Key Highlights

  • Bicara Therapeutics (NASDAQ:BCAX) plunged 45% on October 28, 2026, the largest unexplained biotech drop of the day, and no company release or filing explaining the move was found. This article does not offer a cause.
  • The Justice Department is reportedly inquiring into the roughly USD 13 billion Hugging Face deal of Nvidia (NASDAQ:NVDA), per a report dated October 28, 2026. The report is a single recap and neither side has confirmed an inquiry.
  • Apple (NASDAQ:AAPL) is not on the October 29, 2026 earnings slate. Headline-only search results point to a fiscal fourth-quarter report on November 2, but the date has not been confirmed on the company's investor relations page.
  • Rapport Therapeutics (NASDAQ:RAPP) fell 18% to 23% on October 28, 2026 after pricing about USD 175 million of stock at USD 21.00, roughly 24% below the USD 27.54 close, plus about USD 150 million of convertible notes.

Bicara Therapeutics (NASDAQ:BCAX): A 45% Fall With No News

Bicara Therapeutics fell 45% on October 28, 2026, according to published market data. Inhibrx Biosciences (NASDAQ:INBX) fell 24% the same day, and the two were the largest unexplained biotech declines of the session, meaning a search of company releases and filings found no announcement linked to either move. The cause of both drops is not verified, and a link between them is not established. The absence of a news item does not prove there is no cause, because a company can disclose a development later and large trades can precede it. Analysts usually check new filings, clinical trial registry updates, regulatory notices and moves in related names. For Bicara Therapeutics (NASDAQ:BCAX), the main risk is uncertainty: the fall could be a transient overreaction or the first sign of a bigger issue, and raising equity at a lower price would be more dilutive. Clinical-stage biotechs are especially exposed because one data point can change the value of the whole company, and thin liquidity means selling can push prices down quickly. Watch for any Form 8-K, press release or trial update, and for the regular-session open on October 29.

Nvidia (NASDAQ:NVDA): A Reported Justice Department Inquiry

A report dated October 28, 2026 said the Justice Department is inquiring into the roughly USD 13 billion deal for Hugging Face, the private artificial intelligence platform. The deal value was reported at USD 12.9 billion at signing in August 2026, so the October figure is a rounding. The report comes from a single recap, and no confirmation from the company or the Justice Department was found. An inquiry is an information-gathering step, not a lawsuit, and many reviews end in clearance, sometimes with conditions. The reported antitrust angle is how a dominant chip supplier owning a leading model-sharing hub could affect the wider AI supply chain. Hugging Face is privately held, so it has no ticker. The next scheduled event for Nvidia (NASDAQ:NVDA) is its earnings report on November 17, 2026, where management could face questions. Reviews can include document requests, interviews with competitors and, in some cases, a second request that extends the timeline. For Nvidia (NASDAQ:NVDA), the financial impact of a USD 13 billion deal is small against its scale, but a prolonged review could draw attention to its market power in AI chips.

Apple (NASDAQ:AAPL): A Date Conflict on the Earnings Slate

Apple is not reporting on October 29, 2026, according to headline-only search results that point to a fiscal fourth-quarter report on November 2. Several earlier calendars listed Apple for October 29, so the conflict is genuine, and a calendar error is the most likely explanation. The November 2 date was not confirmed on the investor relations page, so readers should treat it as unverified, because a date seen only in a headline can be an estimate. Apple's fiscal year ends in September, so a fourth-quarter report in early November is consistent with its pattern. If the date holds, it arrives one day before the US midterm elections on November 3, 2026. Holders of Apple (NASDAQ:AAPL) should rely on the company's own confirmation and not on a third-party calendar. Companies announce earnings dates in advance, and calendar sites copy them or estimate them from past patterns, so a wrong date can mislead investors who position for a report that does not arrive. Today's after-the-close slate includes Amazon, Intel, Gilead, SanDisk and Stryker, but not Apple (NASDAQ:AAPL).

Rapport Therapeutics (NASDAQ:RAPP): A Discounted USD 175 Million Raise

Rapport Therapeutics announced the pricing of about USD 175 million of common stock at USD 21.00 per share on October 28, 2026, along with about USD 150 million of convertible notes. The prior close was USD 27.54, so the offering was priced about 24% below it, our arithmetic on two published numbers. Dividing USD 175 million by USD 21.00 implies roughly 8.3 million new shares, also our arithmetic, and the two raises together total roughly USD 325 million. The shares fell between 18% and 23% because published sources differed, and the details come from the offering announcement via a recap, not the prospectus. New shares dilute existing holders, and convertible notes can add more dilution later, though the conversion price was not in the data reviewed. The cash extends the runway for Rapport Therapeutics (NASDAQ:RAPP), which still needs trial results. Offerings are usually priced at a discount to attract buyers quickly, and a 24% discount is wide, which signals that buyers demanded a concession or that the company wanted to raise a large amount fast. Watch for the final prospectus, the closing of the offering and the next clinical update from Rapport Therapeutics (NASDAQ:RAPP).

Where Things Stand

The common thread is how much is still unknown. Bicara fell 45% and no reason has been verified, so Bicara Therapeutics (NASDAQ:BCAX) remains an open question until a filing or release appears. The Nvidia inquiry is reported, not confirmed, and Apple's November 2 date needs the company's own word. Rapport is the clearest case, because its USD 21.00 offering explains the move even though the exact fall ranges from 18% to 23%. The next catalysts are company disclosures, the Nvidia earnings date of November 17 and the closing of the Rapport offering.